Status and phase
Conditions
Treatments
About
This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer.
Full description
Despite the rapid progress of immune-combination therapy in lung cancer, immune-combination anti-vascular regimens after EGFR-TKI failure have not been explored in NSCLC LM, and further exploration of superior regimens targeting brain metastases is needed. Therefore, we plan to conduct an exploratory clinical study of adebenosumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy, with the aim of providing a more feasible and effective comprehensive treatment strategy for this group of patients.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Central trial contact
Jian Zhang, Master; Shengcun Fang, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal